Susquehanna Fundamental Investments’s Intellia Therapeutics NTLA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-69,226	Closed	-$622K	–	628
2025 Q4	$622K	Sell	69,226 -86,978	-56%	-$1.2M	0.02%	405
2025 Q3	$2.7M	Hold	156,204	–	–	0.11%	204
2025 Q2	$1.47M	Hold	156,204	–	–	0.04%	390
2025 Q1	$1.11M	Buy	+156,204	New	+$1.58M	0.02%	666
2021 Q4	–	Sell	-12,438	Closed	-$1.67M	–	1668
2021 Q3	$1.67M	Sell	12,438 -31,617	-72%	-$4.79M	0.03%	657
2021 Q2	$7.13M	Hold	44,055	–	–	0.13%	215
2021 Q1	$3.54M	Hold	44,055	–	–	0.06%	447
2020 Q4	$2.4M	Hold	44,055	–	–	0.04%	572
2020 Q3	$876K	Buy	+44,055	New	+$919K	0.03%	686

Other funds holding NTLA

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments

Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return